focus -WSS

focus

author：knowledge 2025-08-11 08:01:18 - browse：3358

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

hotspot

WSS

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

WHO recommends dropping component of many flu vaccines

FDA panel to weigh approval of NurOwn, controversial ALS drug

Would Medicare drug price negotiations stall in a shutdown?

EpiPen alternative approval delay highlights citizen petition issue

Biotech stock slump in 2023: awaiting the turnaround

hotspot

focus

entertainment

Apple is now the first public company to be valued at $3 trillion

Health tech startups drop sharply from 2021 highs

Walensky prepares to leave CDC — and Congress — behind

Changes to biosimilar regulatory framework must prioritize patients

Tori Bowie and the unacceptable rates of Black maternal death

How AI helped researchers track recovery from depression

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA advisers vote against ALS treatment from BrainStorm

What does generative AI mean for health care? We asked experts

FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

Biotech stock slump in 2023: awaiting the turnaround

STAT Virtual Event: How to Increase Diversity in Clinical Trials

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

CDC advisers recommend seasonal use of Pfizer RSV shot

Covid vaccines: Private market messier than government rollout

Biotech stock slump in 2023: awaiting the turnaround

knowledge

hotspot

hotspot

explore